Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Visualizing T-Cells in Action

Salk scientists used light-sheet superresolution imaging to capture the rearrangement of T-cell receptors from nanometer-scale protein islands (left) to micrometer-scale microclusters (right) after T-cell activation in mouse lymph nodes. [Salk Institute] Scien

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Salk scientists used light-sheet superresolution imaging to capture the rearrangement of T-cell receptors from nanometer-scale protein islands (left) to micrometer-scale microclusters (right) after T-cell activation in mouse lymph nodes. [Salk Institute]

Scientists from the Salk Institute say they have imaged how vital receptors on the surface of T-cells bundle together when activated to fight an invading pathogen. The study (“Superresolution Imaging Reveals Nanometer- and Micrometer-Scale Spatial Distributions of T-Cell Receptors in Lymph Nodes”), published in PNAS, and reportedly the first to visualize this process in lymph nodes, could help scientists better understand how to turn the immune system's activity up or down to treat autoimmune diseases, infections, or even cancer.

“We had seen these receptors cluster and reposition in cultured cells that were artificially stimulated in the lab, but we've never seen their natural arrangements in lymph nodes until now,” says senior author Björn Lillemeier, Ph.D., an associate professor in Salk's Nomis Laboratories for Immunobiology and Microbial Pathogenesis and the Waitt Advanced Biophotonics Center.

Activated T-cells switch on cellular pathways that help the body both actively seek out and destroy the antigens (e.g., virus, bacterium, or cancer cell) and remember it for the future. In the past, by looking at T-cell receptors embedded in isolated cells under the microscope, researchers discovered that the receptors are arranged in clusters of protein islands that merge when the cells are activated.

Dr. Lillemeier wanted more detail on how the receptors are arranged in tissue and how that arrangement might change when the T-cells are activated in living hosts. The team used a superresolution microscope developed in the laboratory of co-senior author Hu Cang, Ph.D., assistant professor at Salk's Waitt Advanced Biophotonics Center and holder of the Frederick B. Rentschler Developmental Chair. This microscopy approach, called light-sheet direct stochastic optical reconstruction microscopy (dSTORM), let the researchers watch T-cell receptors in the membranes of T-cells in mouse lymph nodes at a resolution of approximately 50 nanometers.

The new imagery confirmed the previous observation that protein islands of T-cell receptors merge into larger microclusters when T-cells are activated. But it also showed that, before cells are activated, the protein islands are already arranged in groups, dubbed “territories” by Dr. Lillemeier's team. “The preorganization on the molecular level basically turns the T-cell into a loaded gun,” notes Dr. Lillemeier.

The organization of surface receptors enables T-cells to launch fast and effective immune response against antigens. Understanding how the molecular organization mediates the sensitivity of T-cell responses could help researchers make the immune system more or less sensitive. In the case of autoimmune diseases, clinicians would like to turn down the immune system's activity, whereas turning up the activity could help fight infections or cancers.

The research could also have implications for understanding other receptors in the body that have a wide range of functions both within and outside the immune system. “We think that most receptors on the surfaces of cells are organized like this,” says Ying Hu, Ph.D., first author and postdoctoral researcher at the Salk Institute.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →